The RAS rush: Revolution Medicines bags remarkable $238M IPO raise, more than doubling original goal
Revolution Medicines made it.
Less than a month after pencilling in $100 million for its IPO — divulging some details about its foray into the red hot KRAS race along the way — the biotech is going home with $238 million raised and a new ticker on the Nasdaq: $RVMD.
It did so by offering 14 million shares at $17 each, the top of the range after the biotech revised its terms. Not that its original goal wasn’t already ambitious, aiming between $14 and $16 for 10 million shares.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.